Sununary The effect of anastrozole ('Arimidex', ZD1033), a new, selective, non-steroidal aromatase inhibitor on in vivo aromatisation and plasma oestrogen levels was evaluated in post-menopausal women with breast cancer. Twelve patients progressing after treatment with tamoxifen were randomised to receive anastrozole 1 mg or 10 mg once daily for a 28 day period in a double-blinded crossover design. In vivo aromatisation and plasma oestrogen levels were determined before commencing treatment and at the end of each 4-week period. Breast cancer is the most common malignancy among women in the western hemisphere. Many of these patients develop metastatic disease, for which no cure is currently available. Because endocrine treatment causes fewer side-effects than chemotherapy, such therapy is first-line treatment in patients with metastatic disease and hormone receptor-positive tumours. While the anti-oestrogen tamoxifen is first choice of therapy in post-menopausal patients with metastatic breast cancer. increasing use of tamoxifen as adjuvant therapy focuses on the need for alternative endocrine treatment options on relapse in breast cancer patients.
Breast cancer is the most common malignancy among women in the western hemisphere. Many of these patients develop metastatic disease, for which no cure is currently available. Because endocrine treatment causes fewer side-effects than chemotherapy, such therapy is first-line treatment in patients with metastatic disease and hormone receptor-positive tumours. While the anti-oestrogen tamoxifen is first choice of therapy in post-menopausal patients with metastatic breast cancer. increasing use of tamoxifen as adjuvant therapy focuses on the need for alternative endocrine treatment options on relapse in breast cancer patients.
While ovarian oestrogen synthesis ceases at the menopause, oestrogens are synthesised in peripheral tissue from circulating androgens by the process called aromatisation (Grodin et al., 1973) . The main pathway is conversion of androstenedione (A) into oestrone (El), with a minor contribution from conversion of testosterone into oestradiol (E2) (L0nning et al., 1990) .
Aromatase inhibitors are drugs that inhibit the peripheral conversion of androgens to oestrogens (Santen et al., 1982a) , thereby suppressing plasma oestrogen levels in postmenopausal women. The first-generation aromatase inhibitor, aminoglutethimide, was implemented in breast cancer treatment more than 20 years ago (Cash et al., 1967) . While the drug is effective in hormone-sensitive breast cancer, lack of specificity (inhibition of adrenal steroid-synthesising enzymes) and side-effects (such as skin rash and lethargy) provoked the development of new aromatase inhibitors (Coombes et al., 1984; Evans et al., 1992; Johnston et al., 1994; Lipton et al., 1995; Santen et al., 1989) .
Anastrozole (Arimidex; 2,2'[5-(1H-1 ,2,4-triazol-1-ylmethyl) -1,3-phenylene]bis-(2-methylpropiononitrile, Figure 1 ) is a new, potent and selective aromatase inhibitor belonging to the triazole class. Pilot studies in post-menopausal women have shown the drug to suppress plasma E2 by > 80% (Plourde et al., 1994) , and preclinical studies as well as observations in women suggest the drug to be highly specific with no influence on adrenal steroid synthesis (Plourde et al., 1995) . A major problem in evaluating the biochemical efficacy of aromatase inhibitors has been the lack of internal consistency between the percentage aromatase inhibition and degree of plasma oestrogen suppression. While aminoglutethimide as well as the second-generation aromatase inhibitor formestane and the third-generation inhibitor fadrozole (L0nning et al., 1991) have all been found to inhibit the conversion of A to E1 in vivo by 85-92%, the same drugs have been reported to suppress plasma oestrogen levels by only 50-70% (Vermeulen et al., 1983; Dowsett et al., 1989 Dowsett et al., , 1990 ). Accordingly, a major long-standing controversy has been whether this discrepancy could be caused by alternative oestrogen sources or could simply reflect methodological problems.
The primary aim of this study was to evaluate the effects of two different doses of anastrozole (1 and 10 mg) on in vivo aromatase inhibition and plasma oestrogen suppression in post-menopausal breast cancer patients. A secondary aim was to compare the degree of aromatase inhibition with the degree of plasma oestrogen suppression by applying recently developed, highly sensitive methodology for plasma oestrone sulphate EIS measurement in particular (L0nning and Ekse, 1995). previous tamoxifen treatment were enrolled in the study. The protocol was approved by the regional ethics committee at the University of Bergen. All patients gave their written informed consent. The mean age of the participating patients was 65 years and the mean weight was 67 kg.
Post-menopausal status was defined as age >50 years and no menstruation during the past 5 years or amenorrhoea for less than 5 years with follicle-stimulating hormone (FSH) levels in the post-menopausal range. Women with a druginduced menopausal status (e.g. LHRH treatment) and those who had received treatment with an aromatase inhibitor within the previous 3 months were not eligible for the study.
All patients included had a WHO performance score of 0 -2 at entrance. Patients presenting with life-threatening visceral disease, an estimated survival of less than 3 months or a history of a systemic malignancy other than breast cancer were not eligible.
Of 12 patients that were entered into the study, two (nos. 1 and 2) were protocol deviators and lost for evaluation of in vivo aromatase activity because of administration of an incorrect isotope. One of these patients (no. 1) withdrew from the study having completed the first period of the crossover phase owing to disease progression and thus was lost for evaluation of the alterations in plasma sex hormones. Measurement of whole body aromatisation Aromatisation of A to EB in vivo can be measured by administration of a steady-state infusion or a bolus injection of A and E1 labelled with different isotopes followed by determination of the isotope ratio in plasma or urinary oestrogens respectively. We have developed a high-performance liquid chromatography (HPLC) technique to improve the specificity and sensitivity of measuring the isotope ratio in urinary oestrogen metabolites . A recent formal assessment of sensitivity indicated that inhibition of up to 99.1% was detectable (Dowsett et al., 1995) . In the present study, each patient had in vivo aromatisation determined before commencing treatment and at the end of period I and II by use of this urinary HPLC technique. The injections were administered on day -3, 25 and 53. On each occasion, the patient received a bolus injection of 500 ,uCi
[3H]A and 5 MCi ['4C]EI dissolved in 50 ml saline containing 8% ethanol (w/w). Aliquots of the isotopes in the injection mixture were taken for calculation of the ratio of 3H:'4C. Urine was collected for a period of 96 h, pooled and kept frozen (-20°C) until time of processing.
Urine analysis A detailed description of the analytical method and its reproducibility has been given previously (Jacobs et al., 1991) with slight modifications (Dowsett et al., 1995) . In brief, the pooled urine samples were thawed and about twothirds of the total sample used for analysis. Urinary steroid glucuronides were concentrated on an Amberlite XAD-2 column using water and methanol as mobile phase followed by Sep-pak C18 cartridges and a DEAE Sephadex A-25 column eluted by a salt gradient. The glucuronides were hydrolysed with 1 ml (144 000 units) fl-glucuronidase (Sigma, dissolved in 20 ml 0.1 M acetic acid buffer, pH 4, and incubated at 37°C for 48 h. The unconjugated steroids were separated from the water phase by ether extraction. The ether extract was subsequently washed with sodium bicarbonate (8%). The sodium bicarbonate was acidified by adding hydrochloric acid to a pH of about 2-4, and the oestrogens extracted with ether. The oestrogen fraction was purified on two column systems using DEAE Sephadex with acetic acid buffer (0.05 M, pH 12)-methanol (75:25, w/w) as mobile system and QAE Sephadex in the boric acid form using methanol and acetic acid (0.05 M, pH 9-9.3) in methanol as mobile phase (Fotsis and Adlercreutz, 1987 Plasma sex hormone levels Many patients achieved plasma levels of E2 and E, during treatment that were below the sensitivity limits of the assay, in which case the value was given as the sensitivity limit (Table II and Figure 2 ). Mean plasma level of E, was suppressed from 73.0 pmol 1-1 to 9.7 pmol 1-' (mean suppression of 86.8%) and 9.8 pmol I-' (mean suppression of 86.5%) during treatment with anastrozole 1 mg and 10 mg respectively (P<0.005). Plasma levels of E2 fell from a mean value of 17.7 pmol 1-' before treatment to 2.8 pmol 1-l and 3 .3 nmol 1`and 3.1 nmol`l respectively).
Plasma levels of anastrozole
The mean plasma level of anastrozole was 37.7 ng ml-' (range 22.0-83.9 ng ml-1) during treatment with a drug dose of 1 mg and 341.4 ng ml-1 (range 160.0-644.0 ng ml-') during treatment with a dose of 10 mg daily.
Discussion
Despite the fact that aminoglutethimide has been in clinical use for two decades and several other aromatase inhibitors for 5-10 years, many questions related to their biochemical action remain unaddressed. While the first study evaluating in vivo aromatase inhibition during treatment with aminoglutethimide reported the drug to inhibit the conversion of A to E1 by about 98% (Santen et al., 1978) and contemporary studies by us Jones et al., 1992; L0nning et al., 1991) and others (Reed et al., 1990 ) have found aminoglutethimide, as well as novel aromatase inhibitors such as formestane and fadrozole, to inhibit in vivo aromatisation by about 90%, plasma oestrogens have been found to be sustained at 30-50% of their control levels in patients treated with these drugs (Santen et al., 1982b; Vermeulen et al., 1983; Dowsett et al., 1989 Dowsett et al., ,1990 . Recent studies found the triazole drugs letrozole and vorozole to inhibit in vivo aromatisation by a mean of 98.5% and 93% respectively (Dowsett et al., 1995; Wall et al., 1993 , 1994) , again revealing an internal inconsistency between the degree of aromatase inhibition and percentage of plasma oestrogen suppression. Such a difference could be due either to alternative (non-aromatase-dependent) oestrogen sources or lack of sensitivity of the radioimmunoassays used for plasma oestrogen measurement. Thus, there is a need to compare in vivo aromatase inhibition and plasma oestrogen suppression to develop the concept of aromatase inhibition in breast cancer treatment further.
This study was designed to determine in vivo aromatase inhibition and plasma oestrogen suppression during treatment with anastrozole, a novel aromatase inhibitor. Animal investigations (Plourde et al., 1995) suggest this drug to be a highly potent aromatase inhibitor, and preliminary studies in post-menopausal healthy women and breast cancer patients suggest the drug to be effective in suppressing plasma levels of E2 (Plourde et al., 1994) . To determine in vivo aromatisation, we used a sensitive and specific HPLC assay previously used by our group to evaluate different aromatase inhibitors . Plasma levels of E2 and E, were measured with sensitive methods previously validated in our laboratories (Dowsett et al., 1987; L0nning et al., 1995) . However, owing to low levels of these oestrogens (mean concentration of plasma E2 and E, of about 20 and 75 pmol 1-') in post-menopausal women (L0nning et al., 1995) , it remains difficult to detect>90% suppression of these oestrogens from pretreatment levels. On the other hand, the oestrogen conjugate E,S is found in much higher concentrations than E2 and E, in post-menopausal women. Plasma E2, El and E,S are at equilibrium (L0nning et al., 1990) . Thus, as long as an aromatase inhibitor does not influence enzymes involved in the interconversion of these oestrogens (sulphatase or sulphotransferase) or interacts with oestrogen metabolism (L0nning and Kvinnsland, 1988) , plasma E,S and the unconjugated oestrogens should be expected to be suppressed by the same percentage during treatment with aromatase inhibitors. To measure E,S, we used a highly sensitive assay recently developed to determine plasma levels of this oestrogen in the very low range . Assuming a mean concentration of plasma E,S of about 400 pmol 1' in post-menopausal women, with a sensitivity of 2.7 pmol 1' this assay should be able to detect a 98-99% suppression of this plasma oestrogen conjugate.
This study reveals two important findings. First, it shows anastrozole, given as 1 mg or 10 mg o.d., to inhibit in vivo aromatisation by a mean value of 96.7% and 98.1%, respectively, and so to be one of the most potent aromatase inhibitors investigated so far. Secondly, treatment with anastrozole 1 and 10 mg o.d. suppressed plasma E,S by a mean value of 93.5% and 95.7% respectively. Therefore, our results revealed anastrozole at both doses administered to suppress plasma levels of E,S by a percentage close to the percentage aromatase inhibition. Of note, although without statistical significance, eight out of ten patients experienced a greater degree of E,S suppression when the higher dose of anastrozole was given. While we did not see a similar suppression of plasma EB and E2, it is notable that many patients achieved plasma values of these oestrogens that were below the sensitivity limit of the methods. Thus, it is likely that we underestimated the percentage suppression of plasma E, and E2. These data indicate that with the application of sufficiently sensitive assays, oestrogen suppression and aromatase inhibition are closely parallel in post-menopausal (Yates et al., 1992) , evaluating plasma El and E2 suppression with anastrozole single doses up to 60 mg, suggest that a dose escalation above 1 mg anastrozole once daily may not enhance plasma oestrogen suppression any further.
In conclusion, this study showed anastrozole given as 1 mg or 10 mg o.d. to be highly potent in inhibiting in vivo aromatisation and suppressing plasma oestrogens in postmenopausal breast cancer patients. Our results revealed anastrozole to suppress plasma levels of E,S by a percentage approaching the percentage aromatase inhibition, providing an internal consistency between alterations in the in vivo aromatisation and plasma oestrogen levels in these patients. The findings support the concept that effective aromatase inhibition is accompanied by a profound suppression of plasma oestrogens in post-menopausal breast cancer patients and refute a hypothesis of alternative sources of plasma oestrogens in such patients.
